市場調查報告書

Alpha-1抗胰蛋白酶缺乏症(AATD)流行病學預測 2028年

Alpha-Antitrypsin Deficiency (AATD) - Epidemiology Forecast - 2028

出版商 DelveInsight Business Research LLP 商品編碼 524508
出版日期 內容資訊 英文 100 Pages
商品交期: 最快1-2個工作天內
價格
Back to Top
Alpha-1抗胰蛋白酶缺乏症(AATD)流行病學預測 2028年 Alpha-Antitrypsin Deficiency (AATD) - Epidemiology Forecast - 2028
出版日期: 2019年09月01日內容資訊: 英文 100 Pages
簡介

主要6個國家(美國、英國、德國、法國、義大利、西班牙)的Alpha-1抗胰蛋白酶缺乏症(AATD)患病數在2017年估算為23萬美元5,500人,在2017年∼2028年間預測將逐漸增加。在主要6個國家中,美國的患病人數最多,2017年的患病數估計大約10萬人。

本報告提供主要6個國家(美國,英國,德國,法國,義大利,西班牙)的Alpha-1抗胰蛋白酶缺乏症(AATD)流行病學的相關調查,疾病概要,各地區的患病數的變化與預測(總計12年份),治療流程,未滿足需求,對患者的各種舉措等資訊詳細彙整。

目錄

第1章 報告概要

第2章 疾病的背景和概要:Alpha-1抗胰蛋白酶缺乏症(AATD)

  • 簡介
  • 症狀
  • 病因
  • 危險因素
  • 遺傳形式
  • 病理生理學
  • 併發症
  • 診斷
  • 處理
  • 診斷延遲

第3章 流行病學和患者人口

  • 主要6個國家的患病數
  • 主要6個國家的患病數:各地區
  • 主要6個國家的患病數:分佈情形(成果值)
  • 主要6個國家的患病數:分佈情形(預測值)
  • 流行病學:各國
    • 美國
    • 歐洲5個國家
    • 日本

第4章 治療流程

  • 肺部疾病伴隨的Alpha-1抗胰蛋白酶缺乏症(AATD)的管理
  • 肝疾病伴隨的Alpha-1抗胰蛋白酶缺乏症(AATD)的管理

第5章 未滿足需求

第6章 對Alpha-1抗胰蛋白酶缺乏症(AATD)患者的Grifols舉措

第7章 對Alpha-1抗胰蛋白酶缺乏症(AATD)患者的FDA舉措

第8章 附錄

第9章 調查手法

  • 參考資料

第10章 諮詢服務

第11章 免責聲明

第12章 關於DelveInsight

本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

目錄
Product Code: DIEI0087

DelveInsight's 'Alpha- Antitrypsin Deficiency (AATD) - Market Insights, Epidemiology and Market Forecast-2028' report delivers an in-depth understanding of the disease, historical & forecasted epidemiology trends in the United States, EU5 (Germany, Spain, Italy, France and United Kingdom).

Geography Covered

  • The United States
  • EU5 (Germany, France, Italy, Spain and the United Kingdom)

Study Period: 2017-2028

Alpha- Antitrypsin Deficiency (AATD) - Disease Understanding and Treatment Algorithm

The DelveInsight Alpha- Antitrypsin Deficiency (AATD) market report gives the thorough understanding of the AATD by including details such as disease definition, classification, symptoms, etiology, pathophysiology, diagnostic trends. It also provides treatment algorithms and treatment guidelines for AATD in the US and Europe.

Alpha- Antitrypsin Deficiency (AATD) Epidemiology

The AATD epidemiology division provide the insights about historical and current patient pool and forecasted trend for every 6 major countries. It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. This part of the DelveInsight report also provides the diagnosed and treatable patient pool and their trends along with assumptions undertaken.

The disease epidemiology covered in the report is segmented into two parts: Population at the risk of developing AATD on the basis of allele [PiSS, PiSZ, PiZZ) and Prevalent cases of AATD in 6 Major Markets [United States and EU5 (Germany, Spain, Italy, France and United Kingdom)]. As AATD is quite rare in Japan, the report features the diagnosed population of AATD in Japan.

According to DelveInsight, the prevalent cases of AATD was 235,500 in 2017 in 6MM and, is expected to increase during the study period i.e., 2017-2028. Among 6MM, United States account for highest prevalent cases of AATD with almost 100,000 prevalent cases in 2017. Among the EU5 countries, Germany has the highest prevalent population of AATD with, followed by United Kingdom, which has prevalent population of 27,930 in 2017.

Other than these patients are also segmented based gender and comorbidities associated with Alpha Antitrypsin Deficiency. According to DelveInsight's analysis, in United States there were 2700 liver disease cases associated with AATD in year 2017.

Alpha- Antitrypsin Deficiency (AATD) Report Insights

  • The report covers detailed overview of AATD explaining its causes, symptoms, pathophysiology, diagnosis and treatment patterns.
  • The report provides the insight about the historical and forecasted patient pool for 6 major markets covering the United States & EU5 (Germany, Spain, France, Italy, UK)
  • Patient Population in various epidemiological segments
    • Population at risk of AATD
    • Prevalent Population of AATD
    • Diagnosed Prevalence of AATD
    • Gender Specific case of AATD
    • Comorbidities associated with AATD
  • Therapeutic Approaches

Alpha- Antitrypsin Deficiency (AATD) Report Key Strengths

  • 10 Year Forecast
  • 6MM Coverage
  • Epidemiology Segmentation

Alpha- Antitrypsin Deficiency (AATD) Report Assessment

  • Patient Segmentation
  • Disease Risk & Burden
  • Risk of disease by the segmentation
  • Factors driving growth in a specific patient population
  • Unmet Needs

Key Benefits

  • This DelveInsight report will help to develop Business Strategies by understanding the epidemiology of Alpha- Antitrypsin Deficiency (AATD).
  • The Report helps to recognize the growth opportunities in the 6MM with respect to the patient population
  • Organize research efforts by identifying the best opportunities for AATD disease
  • To understand the future of AATD epidemiology in general population.

Table of Contents

1. Report Introduction

2. Disease Background and Overview: Alpha Antitrypsin Deficiency

  • 2.1. Introduction
  • 2.2. Symptoms
  • 2.3. Etiology
  • 2.4. Risk Factors
  • 2.5. Genetic Inheritance of Alpha Antitrypsin Deficiency
  • 2.6. Pathophysiology
  • 2.7. Complications
  • 2.8. Diagnosis
  • 2.9. Treatment
  • 2.10. Diagnostic Delay

3. Epidemiology and Patient Population

  • 3.1. Prevalent Population of Alpha-1-Antitrypsin Deficiency in 6MM
  • 3.2. Prevalent Population of Alpha-1-Antitrypsin Deficiency in 6MM - By Region
  • 3.3. Prevalent Population of Alpha-1-Antitrypsin Deficiency in 6MM - Distribution (2017)
  • 3.4. Prevalent Population of Alpha-1-Antitrypsin Deficiency in 6MM - Distribution (2028)
  • 3.5. Epidemiology of Alpha-1-Antitrypsin Deficiency- By Country
    • 3.5.1. United States
      • 3.5.1.1. Assumptions and Rationale
      • 3.5.1.2. Population at risk of Alpha Antitrypsin Deficiency in United States
      • 3.5.1.3. Prevalent Population of AATD in The United States
      • 3.5.1.4. Diagnosed Prevalent Population of AATD in The United States
      • 3.5.1.5. Gender- Specific Prevalent Population of AATD in The United States
      • 3.5.1.6. Comorbidities associated with AATD in The United States
    • 3.5.2. EU5
      • 3.5.2.1. Assumptions and Rationale
      • 3.5.2.2. Germany
      • 3.5.2.2.1. Population at risk of Alpha Antitrypsin Deficiency in Germany
      • 3.5.2.2.2. Prevalent Population of Alpha Antitrypsin Deficiency in Germany
      • 3.5.2.2.3. Diagnosed Prevalent Population of AATD in Germany
      • 3.5.2.2.4. Gender- Specific Prevalent Population of AATD in Germany
      • 3.5.2.2.5. Comorbidities associated with AATD in Germany
      • 3.5.2.3. France
      • 3.5.2.3.1. Population at risk of Alpha Antitrypsin Deficiency in France
      • 3.5.2.3.2. Prevalent Population of Alpha Antitrypsin Deficiency in France
      • 3.5.2.3.3. Diagnosed Prevalent Population of AATD in France
      • 3.5.2.3.4. Gender- Specific Prevalent Population of AATD in France
      • 3.5.2.3.5. Comorbidities associated with AATD in France
      • 3.5.2.4. Italy
      • 3.5.2.4.1. Population at risk of Alpha Antitrypsin Deficiency in Italy
      • 3.5.2.4.2. Prevalent Population of Alpha Antitrypsin Deficiency in Italy
      • 3.5.2.4.3. Diagnosed Prevalent Population of AATD in Italy
      • 3.5.2.4.4. Gender- Specific Prevalent Population of AATD in Italy
      • 3.5.2.4.5. Comorbidities associated with AATD in Italy
      • 3.5.2.5. Spain
      • 3.5.2.5.1. Population at risk of Alpha Antitrypsin Deficiency in Spain
      • 3.5.2.5.2. Prevalent Population of Alpha Antitrypsin Deficiency in Spain
      • 3.5.2.5.3. Diagnosed Prevalent Population of AATD in Spain
      • 3.5.2.5.4. Gender- Specific Prevalent Population of AATD in Spain
      • 3.5.2.5.5. Comorbidities associated with AATD in Spain
      • 3.5.2.6. United Kingdom
      • 3.5.2.6.1. Population at risk of Alpha Antitrypsin Deficiency in The UK
      • 3.5.2.6.2. Prevalent Population of Alpha Antitrypsin Deficiency in The UK
      • 3.5.2.6.3. Diagnosed Prevalent Population of AATD in The UK
      • 3.5.2.6.4. Gender- Specific Prevalent Population of AATD in The UK
      • 3.5.2.6.5. Comorbidities associated with AATD in The UK
    • 3.5.3. Japan
      • 3.5.3.1. Diagnosed Population of Alpha Antitrypsin Deficiency in Japan

To be continued in the report

4. Treatment Algorithm

  • 4.1. Management of Alpha-Antitrypsin (AAT) Deficiency with Lung Disease
  • 4.2. Management of Alpha-Antitrypsin (AAT) Deficiency with Liver Disease

5. Unmet Needs

6. Grifols Initiatives towards Alpha Anti-trypsin deficiency

7. USFDA Initiatives for patients with Alpha-1 Antitrypsin Deficiency (AATD)

8. Appendix

9. Report Methodology

  • 9.1. Sources Used

10. Consulting Services

11. Disclaimer

12. About DelveInsight

List of Tables

  • TABLE 1: DIAGNOSTIC DELAY INTERVAL FOR AATD
  • TABLE 2: TOTAL PREVALENT POPULATION OF ALPHA-1-ANTITRYPSIN DEFICIENCY IN 6 MM (2017-2028)
  • TABLE 3: POPULATION AT RISK OF ALPHA ANTITRYPSIN DEFICIENCY IN UNITED STATES (2017-2028)
  • TABLE 4: PREVALENT POPULATION OF ALPHA ANTITRYPSIN DEFICIENCY IN UNITED STATES (2017-2028)
  • TABLE 5: DIAGNOSED PREVALENT POPULATION OF ALPHA ANTITRYPSIN DEFICIENCY IN UNITED STATES (2017-2028)
  • TABLE 6: GENDER- SPECIFIC PREVALENT POPULATION OF ALPHA ANTITRYPSIN DEFICIENCY IN UNITED STATES (2017-2028)
  • TABLE 7: COMORBIDITIES ASSOCIATED WITH ALPHA ANTITRYPSIN DEFICIENCY IN UNITED STATES (2017-2028)
  • TABLE 8: POPULATION AT RISK OF ALPHA ANTITRYPSIN DEFICIENCY IN GERMANY (2017-2028)
  • TABLE 9: PREVALENT POPULATION OF ALPHA ANTITRYPSIN DEFICIENCY IN GERMANY (2017-2028)
  • TABLE 10: DIAGNOSED PREVALENT POPULATION OF ALPHA ANTITRYPSIN DEFICIENCY IN GERMANY (2017-2028)
  • TABLE 11: GENDER- SPECIFIC PREVALENT POPULATION OF ALPHA ANTITRYPSIN DEFICIENCY IN GERMANY (2017-2028)
  • TABLE 12: COMORBIDITIES ASSOCIATED WITH ALPHA ANTITRYPSIN DEFICIENCY IN GERMANY (2017-2028)
  • TABLE 13: POPULATION AT RISK OF ALPHA ANTITRYPSIN DEFICIENCY IN FRANCE (2017-2028)
  • TABLE 14: PREVALENT POPULATION OF ALPHA ANTITRYPSIN DEFICIENCY IN FRANCE (2017-2028)
  • TABLE 15: DIAGNOSED PREVALENT POPULATION OF ALPHA ANTITRYPSIN DEFICIENCY IN FRANCE (2017-2028)
  • TABLE 16: GENDER- SPECIFIC PREVALENT POPULATION OF ALPHA ANTITRYPSIN DEFICIENCY IN FRANCE (2017-2028)
  • TABLE 17: COMORBIDITIES ASSOCIATED WITH ALPHA ANTITRYPSIN DEFICIENCY IN FRANCE (2017-2028)
  • TABLE 18: POPULATION AT RISK OF ALPHA ANTITRYPSIN DEFICIENCY IN ITALY (2017-2028)
  • TABLE 19: PREVALENT POPULATION OF ALPHA ANTITRYPSIN DEFICIENCY IN ITALY (2017-2028)
  • TABLE 20: DIAGNOSED PREVALENT POPULATION OF ALPHA ANTITRYPSIN DEFICIENCY IN ITALY (2017-2028)
  • TABLE 21: GENDER- SPECIFIC PREVALENT POPULATION OF ALPHA ANTITRYPSIN DEFICIENCY IN ITALY (2017-2028)
  • TABLE 22: COMORBIDITIES ASSOCIATED WITH ALPHA ANTITRYPSIN DEFICIENCY IN ITALY (2017-2028)
  • TABLE 23: POPULATION AT RISK OF ALPHA ANTITRYPSIN DEFICIENCY IN SPAIN (2017-2028)
  • TABLE 24: PREVALENT POPULATION OF ALPHA ANTITRYPSIN DEFICIENCY IN SPAIN (2017-2028)
  • TABLE 25: DIAGNOSED PREVALENT POPULATION OF ALPHA ANTITRYPSIN DEFICIENCY IN SPAIN (2017-2028)
  • TABLE 26: GENDER- SPECIFIC PREVALENT POPULATION OF ALPHA ANTITRYPSIN DEFICIENCY IN SPAIN (2017-2028)
  • TABLE 27: COMORBIDITIES ASSOCIATED WITH ALPHA ANTITRYPSIN DEFICIENCY IN SPAIN (2017-2028)
  • TABLE 28: POPULATION AT RISK OF ALPHA ANTITRYPSIN DEFICIENCY IN UNITED KINGDOM (2017-2028)
  • TABLE 29: PREVALENT POPULATION OF ALPHA ANTITRYPSIN DEFICIENCY IN UNITED KINGDOM (2017-2028)
  • TABLE 30: DIAGNOSED PREVALENT POPULATION OF ALPHA ANTITRYPSIN DEFICIENCY IN UK (2017-2028)
  • TABLE 31: GENDER- SPECIFIC PREVALENT POPULATION OF ALPHA ANTITRYPSIN DEFICIENCY IN UK (2017-2028)
  • TABLE 32: COMORBIDITIES ASSOCIATED WITH ALPHA ANTITRYPSIN DEFICIENCY IN UK (2017-2028)
  • TABLE 33: DIAGNOSED POPULATION OF ALPHA ANTITRYPSIN DEFICIENCY IN JAPAN (2017-2028)

List of Figures

  • FIGURE 1: RISK FACTORS FOR AATD
  • FIGURE 2: RISK FACTORS FOR AATD
  • FIGURE 3: RISK FACTORS FOR AATD
  • FIGURE 4: ALPHA-1 ANTITRYPSIN BINDS AND INACTIVATES NEUTROPHIL ELASTASE.
  • FIGURE 5: PATHOGENESIS OF ALPHA ANTITRYPSIN DEFICIENCY
  • FIGURE 6: DIAGNOSTIC ALGORITHM OF ALPHA ANTITRYPSIN DEFICIENCY
  • FIGURE 7: GENERAL TREATMENT OF ALPHA ANTITRYPSIN DEFICIENCY
  • FIGURE 8: STRATEGIES FOR DELIVERY OF ENGINEERED NUCLEASES: A) EX-VIVO ; B) IN VIVO
  • FIGURE 9:GENOME EDITING WITH ENGINEERED NUCLEASES
  • FIGURE 10: TOTAL PREVALENT POPULATION OF ALPHA-1-ANTITRYPSIN DEFICIENCY IN 6 MM (2017-2028)
  • FIGURE 11: POPULATION AT RISK OF ALPHA ANTITRYPSIN DEFICIENCY IN UNITED STATES (2017-2028)
  • FIGURE 12: PREVALENT POPULATION OF ALPHA ANTITRYPSIN DEFICIENCY IN UNITED STATES (2017-2028)
  • FIGURE 13: DIAGNOSED PREVALENT POPULATION OF ALPHA ANTITRYPSIN DEFICIENCY IN UNITED STATES (2017-2028)
  • FIGURE 14: GENDER- SPECIFIC PREVALENT POPULATION OF ALPHA ANTITRYPSIN DEFICIENCY IN UNITED STATES (2017-2028)
  • FIGURE 15: COMORBIDITIES ASSOCIATED WITH ALPHA ANTITRYPSIN DEFICIENCY IN UNITED STATES (2017-2028)
  • FIGURE 16: POPULATION AT RISK OF ALPHA ANTITRYPSIN DEFICIENCY IN GERMANY (2017-2028)
  • FIGURE 17: PREVALENT POPULATION OF ALPHA ANTITRYPSIN DEFICIENCY IN GERMANY (2017-2028)
  • FIGURE 18: DIAGNOSED PREVALENT POPULATION OF ALPHA ANTITRYPSIN DEFICIENCY IN GERMANY (2017-2028)
  • FIGURE 19: GENDER- SPECIFIC PREVALENT POPULATION OF ALPHA ANTITRYPSIN DEFICIENCY IN GERMANY (2017-2028)
  • FIGURE 20: COMORBIDITIES ASSOCIATED WITH ALPHA ANTITRYPSIN DEFICIENCY IN GERMANY (2017-2028)
  • FIGURE 21: POPULATION AT RISK OF ALPHA ANTITRYPSIN DEFICIENCY IN FRANCE (2017-2028)
  • FIGURE 22: PREVALENT POPULATION OF ALPHA ANTITRYPSIN DEFICIENCY IN FRANCE (2017-2028)
  • FIGURE 23: DIAGNOSED PREVALENT POPULATION OF ALPHA ANTITRYPSIN DEFICIENCY IN FRANCE (2017-2028)
  • FIGURE 24: GENDER- SPECIFIC PREVALENT POPULATION OF ALPHA ANTITRYPSIN DEFICIENCY IN FRANCE (2017-2028)
  • FIGURE 25: COMORBIDITIES ASSOCIATED WITH ALPHA ANTITRYPSIN DEFICIENCY IN FRANCE (2017-2028)
  • FIGURE 26: POPULATION AT RISK OF ALPHA ANTITRYPSIN DEFICIENCY IN ITALY (2017-2028)
  • FIGURE 27: PREVALENT POPULATION OF ALPHA ANTITRYPSIN DEFICIENCY IN ITALY (2017-2028)
  • FIGURE 28: DIAGNOSED PREVALENT POPULATION OF ALPHA ANTITRYPSIN DEFICIENCY IN ITALY (2017-2028)
  • FIGURE 29: GENDER- SPECIFIC PREVALENT POPULATION OF ALPHA ANTITRYPSIN DEFICIENCY IN ITALY (2017-2028)
  • FIGURE 30: COMORBIDITIES ASSOCIATED WITH ALPHA ANTITRYPSIN DEFICIENCY IN ITALY (2017-2028)
  • FIGURE 31: POPULATION AT RISK OF ALPHA ANTITRYPSIN DEFICIENCY IN SPAIN ( (2017-2028)
  • FIGURE 32: PREVALENT POPULATION OF ALPHA ANTITRYPSIN DEFICIENCY IN SPAIN (2017-2028)
  • FIGURE 33: DIAGNOSED PREVALENT POPULATION OF ALPHA ANTITRYPSIN DEFICIENCY IN SPAIN (2017-2028)
  • FIGURE 34: GENDER- SPECIFIC PREVALENT POPULATION OF ALPHA ANTITRYPSIN DEFICIENCY IN SPAIN (2017-2028)
  • FIGURE 35: COMORBIDITIES ASSOCIATED WITH ALPHA ANTITRYPSIN DEFICIENCY IN SPAIN (2017-2028)
  • FIGURE 36: POPULATION AT RISK OF ALPHA ANTITRYPSIN DEFICIENCY IN UNITED KINGDOM (2017-2028)
  • FIGURE 37: PREVALENT POPULATION OF ALPHA ANTITRYPSIN DEFICIENCY IN UNITED KINGDOM (2017-2028)
  • FIGURE 38: DIAGNOSED PREVALENT POPULATION OF ALPHA ANTITRYPSIN DEFICIENCY IN UK (2017-2028)
  • FIGURE 39: GENDER- SPECIFIC PREVALENT POPULATION OF ALPHA ANTITRYPSIN DEFICIENCY IN UK (2017-2028)
  • FIGURE 40: COMORBIDITIES ASSOCIATED WITH ALPHA ANTITRYPSIN DEFICIENCY IN UK (2017-2028)
  • FIGURE 41: DIAGNOSED PREVALENT POPULATION OF ALPHA ANTITRYPSIN DEFICIENCY IN JAPAN (2017-2028)
Back to Top